CARMOD - Golcadomide (BMS-986369) post-CAR T-cell in R/R Aggressive large B-cell lymphoma patients with high risk of relapse

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506705-20-00

Enrollment

Registered

2024-04-05

Start date

2024-06-14

Completion date

Unknown

Last updated

2024-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed or refractory patients with aggressive large B-cell lymphoma at high risk of relapse

Brief summary

Efficacy determination will be based upon the primary endpoint of complete metabolic response (CMR) rate at 3 months after infusion of anti-CD19 CAR T-cell assessed by study investigator.

Detailed description

Objective response rate (ORR), Complete metabolic response (CMR), Partial metabolic response (PMR), Duration of response (DoR), Event-free survival (EFS), Progression-free survival (PFS), Time to next anti-lymphoma therapy (TTNLT), Overall survival (OS)

Interventions

DRUGYESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

DRUGGolcadomide

DRUGBreyanzi 1.1-70 × 106 cells/mL / 1.1-70 × 106 cells/mL dispersion for infusion

DRUGKymriah 1.2 x 10^6 – 6 x 10^8 cells dispersion for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Efficacy determination will be based upon the primary endpoint of complete metabolic response (CMR) rate at 3 months after infusion of anti-CD19 CAR T-cell assessed by study investigator.	—

Secondary

Measure	Time frame
Objective response rate (ORR), Complete metabolic response (CMR), Partial metabolic response (PMR), Duration of response (DoR), Event-free survival (EFS), Progression-free survival (PFS), Time to next anti-lymphoma therapy (TTNLT), Overall survival (OS)	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026